Visudyne® approved in Japan

October 16, 2003 01:30 ET | Source: Novartis Pharma AG Novartis Pharma AG

Visudyne® approved in Japan for treatment of Age-Related Macular Degeneration (AMD)

Basel, Switzerland and Vancouver, Canada, 16 October 2003 - Novartis Pharma AG, Ophthalmics, the eye health unit of Novartis AG and QLT Inc., announced today that health authorities in Japan have approved Visudyne® (verteporfin) for the treatment of the "wet" form of Age-Related Macular Degeneration (AMD), the leading cause of blindness in people over age 50.

Please see full press release under the following link:

Attachments

Novartis Release

Novartis Release...

Recommended Reading

March 29, 2026 01:15 ET | Source: Novartis Pharma AG

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta...
Read More
March 27, 2026 02:00 ET | Source: Novartis Pharma AG

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism...
Read More